The emerging safety profile of JAK inhibitors in rheumatic disease

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0185 Tofacitinib, An Oral JAK Inhibitor, in The Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

(2016) J. Wollenhaupt et al.   ANNALS OF THE RHEUMATIC DISEASES

SP0104 Neutrophils in The Resolution of Inflammation

(2016) M. Herrmann   ANNALS OF THE RHEUMATIC DISEASES

SP0097 Intracellular MTX Polyglutamates and Clinical Response

(2016) R. de Jonge   ANNALS OF THE RHEUMATIC DISEASES

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

(2016) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2016) Mark C. Genovese et al.   Arthritis & Rheumatology

A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy

(2016) Joel M. Kremer et al.   Arthritis & Rheumatology

Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

(2016) Fenglong Xie et al.   Arthritis & Rheumatology

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014

(2015) A. Marren et al.   ANNALS OF THE RHEUMATIC DISEASES

SP0027 One for All – Patient Research Partners Involved in Disseminating Eular Recommendations Among Belgium Patients

(2015) I. De Keyser   ANNALS OF THE RHEUMATIC DISEASES

OP0025-PARE Campaign Against the Shortage of Rheumatology Professionals

(2015) M. Ekroth et al.   ANNALS OF THE RHEUMATIC DISEASES

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

(2015) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

(2015) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

(2015) Himal Lal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

(2015) Alessandro M. Vannucchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

(2015) Joel M Kremer et al.   ARTHRITIS RESEARCH & THERAPY

A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis

(2015) Roy M. Fleischmann et al.   Arthritis & Rheumatology

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis

(2015) Mark C. Genovese et al.   Arthritis & Rheumatology

Long-term Persistence of Zoster Vaccine Efficacy

(2014) Vicki A. Morrison et al.   CLINICAL INFECTIOUS DISEASES

Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases

(2014) James D. Clark et al.   JOURNAL OF MEDICINAL CHEMISTRY

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis

(2014) Chul Won Jung et al.   LEUKEMIA & LYMPHOMA

Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

(2014) Stanley Cohen et al.   Arthritis & Rheumatology

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials

(2013) V P Bykerk et al.   ANNALS OF THE RHEUMATIC DISEASES

2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host

(2013) Lorry G. Rubin et al.   CLINICAL INFECTIOUS DISEASES

Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster

(2013) Kevin L. Winthrop et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program

(2013) M. E. Weinblatt et al.   JOURNAL OF RHEUMATOLOGY

Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

(2013) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

Back to the future: oral targeted therapy for RA and other autoimmune diseases

(2013) John J. O'Shea et al.   Nature Reviews Rheumatology

Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib

(2013) Rowan Wathes et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAKs and STATs in Immunity, Immunodeficiency, and Cancer

(2013) John J. O'Shea et al.   NEW ENGLAND JOURNAL OF MEDICINE

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease

(2012) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

(2012) John J. O'Shea et al.   IMMUNITY

Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans

(2011) Gabriela Schmajuk et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

(2011) Mark S. Diamond et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Varicella Zoster Virus DNA at Inoculation Sites and in Saliva After Zostavax Immunization

(2011) Duane L. Pierson et al.   JOURNAL OF INFECTIOUS DISEASES

Functional Correlations of Pathogenesis-Driven Gene Expression Signatures in Tuberculosis

(2011) Jeroen Maertzdorf et al.   PLoS One

Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy

(2010) K. L. Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Identification of a Potent Janus Kinase 3 Inhibitor with High Selectivity within the Janus Kinase Family

(2010) Gebhard Thoma et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

(2010) Johan Askling et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

A partial form of recessive STAT1 deficiency in humans

(2009) Ariane Chapgier et al.   JOURNAL OF CLINICAL INVESTIGATION

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

(2008) T A Simon et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Cytokine Signaling Modules in Inflammatory Responses

(2008) John J. O'Shea et al.   IMMUNITY